Filing Details

Accession Number:
0001209191-10-049949
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-10-12 09:49:37
Reporting Period:
2010-10-07
Filing Date:
2010-10-12
Accepted Time:
2010-10-12 09:49:37
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1009356 Salix Pharmaceuticals Ltd SLXP Pharmaceutical Preparations (2834) 943267443
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1212667 Thomas Alonzo D 1700 Perimeter Park Drive
Morrisville NC 27560
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2010-10-07 260 $38.00 260 No 4 P Indirect By LP
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By LP
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 65,680 Direct
Common Stock 2,550 Indirect By LLC
Common Stock 6,500 Indirect By Wife
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Option to Buy Common Stock $17.63 2015-06-09 15,000 15,000 Direct
Common Stock Option to Buy Common Stock $18.87 2014-06-17 22,500 22,500 Direct
Common Stock Option to Buy Common Stock $7.60 2013-07-24 15,000 15,000 Direct
Common Stock Option to Buy Common Stock $4.07 2012-07-02 15,000 15,000 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2015-06-09 15,000 15,000 Direct
2014-06-17 22,500 22,500 Direct
2013-07-24 15,000 15,000 Direct
2012-07-02 15,000 15,000 Direct
Footnotes
  1. The securities are held by Westover Partnership, of which the reporting person is a general partner. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of the reported securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
  2. Options are 100% vested.